• Viperin Interferes with Coronavirus RTC via nsp8 Disruption

  2026-06-18

  This study elucidates a previously unrecognized antiviral mechanism by which viperin, an interferon-induced protein, inhibits coronavirus replication. By directly targeting non-structural protein 8 (nsp8), viperin disrupts assembly of the replication-transcription complex (RTC), expanding the understanding of host-driven coronavirus restriction and offering new potential targets for broad-spectrum antiviral development.

• Methylprednisolone Sodium Succinate: Mechanistic Leverage fo

  2026-06-18

  This thought-leadership article explores the mechanistic depth and translational strategy surrounding Methylprednisolone Sodium Succinate, a synthetic corticosteroid pivotal for inflammation and immunology research. It connects molecular insights with actionable protocols, contrasts competitive solutions, and outlines a visionary framework for maximizing reproducibility and impact in preclinical and translational studies.

• Quantifying Drug-Induced Fractional Killing via High-Through

  2026-06-17

  Inde et al. present a robust protocol for quantifying drug-induced fractional killing in cancer cell populations using high-throughput microscopy. This methodological advance enables precise, parallel comparison of cytotoxic responses across hundreds of experimental conditions, providing critical insight into the heterogeneity of cell death induced by kinase inhibitors.

• BMS-777607: Selective c-Met Inhibitor for Cancer Research

  2026-06-17

  BMS-777607 is a potent, selective c-Met inhibitor targeting key receptor tyrosine kinases. It demonstrates sub-nanomolar IC50 values for c-Met, Axl, Ron, and Tyro3, with high selectivity and oral bioavailability. This compound is validated in cancer and stem cell research for inhibiting MET signaling and suppressing metastasis.

• BMS 599626 Dihydrochloride: Precision EGFR/ErbB2 Inhibition

  2026-06-16

  Explore how BMS 599626 dihydrochloride, a potent EGFR and ErbB2 inhibitor, advances mechanistic cancer research and selective pathway interrogation. This article uniquely dissects molecular selectivity, assay design, and AI-driven discovery—bridging practical protocols with emerging senolytic insights.

• Paroxetine Mesylate: SSRI Polypharmacology in Oncology Innov

  2026-06-16

  Explore how Paroxetine Mesylate, a selective serotonin reuptake inhibitor, is reshaping translational research with its multi-targeted mechanisms—from classic psychiatric applications to novel roles as a MET and ERBB3 inhibitor in colorectal cancer. This article delivers mechanistic insights, protocol guidance, and strategic perspectives for researchers seeking to bridge neuropharmacology and oncology.

• METTL17 Regulates Ferroptosis and Tumorigenesis in Colorecta

  2026-06-15

  This study uncovers how METTL17, a mitochondrial RNA methyltransferase, regulates ferroptosis resistance and tumorigenesis in colorectal cancer by modulating mitochondrial translation. By revealing a previously uncharacterized mitochondrial defense mechanism, the findings highlight METTL17 as a promising therapeutic target to sensitize colorectal tumors to ferroptosis-based interventions.

• Toremifene as a Molecular Probe: Advancing Prostate Cancer P

  2026-06-15

  Explore how Toremifene, a selective estrogen-receptor modulator, enables advanced dissection of hormone and calcium signaling in prostate cancer research. This article offers new insights into protocol design, assay optimization, and mechanistic studies beyond current literature.

• D-Lin-MC3-DMA: Mechanistic Insights and Strategic Leverage i

  2026-06-14

  Explore how D-Lin-MC3-DMA, the gold-standard ionizable cationic liposome, is reshaping translational RNA therapeutics through molecular innovation, experimental rigor, and predictive optimization. This thought-leadership article provides actionable guidance for researchers bridging bench to bedside in siRNA and mRNA delivery workflows.

• Endothelial SGK1 Mediates Salt-Induced Vascular Stiffening

  2026-06-13

  Recent research demonstrates that endothelial SGK1 is a key mediator of vascular stiffening in salt-sensitive conditions. Genetic deletion or pharmacological inhibition of SGK1, notably with EMD638683, attenuates endothelial and arterial stiffness by interfering with sodium channel regulation and actin polymerization, offering mechanistic insight into cardiovascular disease pathogenesis.

• AG-490 (Tyrphostin B42): Precision JAK2/STAT6 Inhibition in

  2026-06-12

  AG-490 (Tyrphostin B42) empowers researchers to dissect oncogenic signaling and immune modulation in hepatocellular carcinoma by targeting the JAK2/STAT6 pathway. Its solubility, specificity, and translational relevance set it apart for exosome-macrophage research and advanced immunopathological state suppression.

• Machine Learning Accelerates Discovery of Novel Senolytics

  2026-06-12

  The referenced study pioneers the use of machine learning to identify potent senolytic compounds, reducing the costs and barriers of traditional drug screening. This approach validates three new candidates and demonstrates the impact of AI-driven strategies in targeting cellular senescence for cancer and aging research.

• BMS-777607: Selective c-Met Inhibitor for MET Pathway Resear

  2026-06-11

  BMS-777607 is a potent, orally available c-Met inhibitor with nanomolar selectivity for MET kinase family members. Evidence demonstrates its efficacy in tumor growth inhibition and its role as a key tool for MET signaling pathway research. The compound enables advanced cancer and stem cell modeling with well-characterized biochemical and pharmacological properties.

• Glucocorticoid Receptor Control of Hippocampal CYPs in Neuro

  2026-06-11

  Nkosi and Maseko's study uncovers a glucocorticoid receptor-dependent, pregnane X receptor (PXR)-independent pathway by which pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 (CYP) enzymes and protects against phenytoin-induced neurotoxicity. These findings challenge hepatic-centric paradigms of CYP regulation and highlight new neuroprotective strategies targeting brain-specific steroid metabolism.

• Rapamycin (Sirolimus): Advanced mTOR Inhibition Workflows

  2026-06-10

  Rapamycin (Sirolimus) from APExBIO enables precise, reproducible inhibition of mTOR signaling—empowering research in cancer biology, immunology, and mitochondrial disease models. This article guides you through optimized protocols, troubleshooting tips, and translational insights from the latest reference study on autophagy modulation in Candida albicans.

15838 records 1/1056 page Next 12345 下5页 Last page